


PHARMACEUTICAL 2021

LANDEC

LANDEC CORP \CA\ Rank 100 of 409







RealRate

PHARMACEUTICAL 2021

LANDEC CORP \CA Rank 100 of 409



The relative strengths and weaknesses of LANDEC CORP \CA\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LANDEC CORP \CA\ compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 495% points. The greatest weakness of LANDEC CORP \CA\ is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 454% points.

The company's Economic Capital Ratio, given in the ranking table, is 22%, being 377% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	157,107
Cost of Goods Sold	515,378
Intangible Assets	69,386
Liabilities, Current	164,388
Liabilities, Non-Current	105,915
Other Assets	122,482
Other Compr. Net Income	-2,872
Other Expenses	26,725
Other Liabilities	39,966
Other Net Income	-3,167
Property and Equipment	192,338
Research and Development	11,099
Revenues	590,366
Selling, General and Administrative Expense	72,188

Output Variable	Value in 1000 USD
Assets	541,313
Liabilities	310,269
Expenses	625,390
Stockholders Equity	231,044
Net Income	-38,191
Comprehensive Net Income	-39,627
Economic Capital Ratio	22%

